Cellink has finalized a definitive agreement to acquire Scienion in a move designed to fundamentally transform its role in the global diagnostics and pharmaceutical markets. The strategic rationale for this transaction centers on a "vertical-integration" play, merging the target's industry-leading technical operational depth in precision picoliter dispensing with the group’s established global leadership in bioprinting and single-cell handling. This structural alignment provides the organization with the scientific talent and high-performance hardware—specifically the target's proprietary dispensing platforms—required to address the increasing demand for standardized high-throughput production of clinically approved diagnostic devices.

SCIENION, which reported an EBITDA margin of LOGIN in 2019, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN premium to the 10.6x average currently observed in the Industry & Manufacturing sector.

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.